Preview

Кардиология

Расширенный поиск

Плейотропные эффекты эзетимиба

https://doi.org/10.18087/cardio.n875

Полный текст:

Аннотация

В обзоре подробно рассматривается вопрос о дополнительных позитивных эффектах эзетимиба, помимо прямого гиполипидемического действия. Приводятся данные экспериментальных и клинических исследований, в которых изучалось влияние эзетимиба на углеводный обмен, воспаление, эндотелиальную функцию и печень. Также обсуждаются результаты клинических исследований, в которых изучалось влияние эзетимиба на атеросклеротическую бляшку.

Об авторах

И. И. Шапошник
ФГБОУ ВО «Южно-Уральский государственный медицинский университет» МЗ РФ
Россия

454092, Челябинск, ул. Воровского, 64



В. В. Генкель
ФГБОУ ВО «Южно-Уральский государственный медицинский университет» МЗ РФ
Россия

454092, Челябинск, ул. Воровского, 64



Список литературы

1. Ежов М. В., Сергиенко И. В., Аронов Д. М., Арабидзе Г. Г., Ахмеджанов Н. М., Бажан С. С. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации VI пересмотр. Атеросклероз и дислипидемии. 2017;3(28):5-22

2. Oesterle A, Laufs U, Liao JK. Pleiotropic Effects of Statins on the Cardiovascular System. Circulation Research. 2017;120(1):229–43. DOI:10.1161/CIRCRESAHA.116.308537

3. Dolezelova E, Stein E, Derosa G, Maffioli P, Nachtigal P, Sahebkar A. Effect of ezetimibe on plasma adipokines: a systematic review and meta- analysis. British Journal of Clinical Pharmacology. 2017;83(7):1380–96. DOI:10.1111/bcp.13250

4. Фесенко Э.В., Прощаев К.И., Поляков В.И. Плейотропные эффекты статинотерапии и их роль в преодолении проблемы полиморбидности. Современные проблемы науки и образования. 2012; 2:48

5. Jia L, Betters JL, Yu L. Niemann-Pick C1-Like 1 (NPC1L1) Protein in Intestinal and Hepatic Cholesterol Transport. Annual Review of Physiology. 2011;73(1):239–59. DOI:10.1146/annurev-physiol-012110-142233

6. Yu L, Li-Hawkins J, Hammer RE, Berge KE, Horton JD, Cohen JC et al. Overexpression of ABCG5 and ABCG8 promotes biliary choles- terol secretion and reduces fractional absorption of dietary cholesterol. Journal of Clinical Investigation. 2002;110(5):671–80. DOI:10.1172/JCI0216001

7. Sugiyama S, Jinnouchi H, Hieshima K, Kurinami N, Suzuki T, Miyamoto F et al. A pilot study of ezetimibe vs. atorvastatin for improv- ing peripheral microvascular endothelial function in stable patients with type 2 diabetes mellitus. Lipids in Health and Disease. 2015;14(1):37. DOI:10.1186/s12944-015-0028-z

8. Kurobe H, Aihara K, Higashida M, Hirata Y, Nishiya M, Matsuoka Y et al. Ezetimibe Monotherapy Ameliorates Vascular Function in Patients with Hypercholesterolemia Through Decreasing Oxidative Stress. Journal of Atherosclerosis and Thrombosis. 2011;18(12):1080–9. DOI:10.5551/jat.9548

9. Grigore L, Raselli S, Garlaschelli K, Redaelli L, Norata GD, Pirillo A et al. Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia. European Journal of Clinical Pharmacology. 2013;69(3):341–6. DOI:10.1007/s00228-012-1345-z

10. Takase S, Matoba T, Nakashiro S, Mukai Y, Inoue S, Oi K et al. Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting: The CuVIC Trial (Effect of Choles- terol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting), a Multicenter Randomized Controlled Trial. Arteriosclerosis, Thrombosis, and Vascular Biology. 2017;37(2):350–8. DOI:10.1161/ATVBAHA.116.308388

11. Qin J, Wang L, Liu Z, Zou Y, Fei Y, Liu Z. Ezetimibe Protects Endothelial Cells against Oxidative Stress through Akt/GSK-3β Pathway. Current Medical Science. 2018;38(3):398–404. DOI:10.1007/s11596-018-1892-3

12. Kostapanos MS, Spyrou AT, Tellis CC, Gazi IF, Tselepis AD, Elisaf M et al. Ezetimibe Treatment Lowers Indicators of Oxidative Stress in Hypercholesterolemic Subjects with High Oxidative Stress. Lipids. 2011;46(4):341–8. DOI:10.1007/s11745-011-3539-z

13. Zimmer S, Grebe A, Latz E. Danger Signaling in Atherosclerosis. Circulation Research. 2015;116(2):323–40. DOI:10.1161/CIRCRESAHA.116.301135

14. Tie C, Gao K, Zhang N, Zhang S, Shen J, Xie X et al. Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition. PLOS ONE. 2015;10(11): e0142430. DOI:10.1371/journal.pone.0142430

15. Ren Y, Zhu H, Fan Z, Gao Y, Tian N. Comparison of the effect of rosuv- astatin versus rosuvastatin/ezetimibe on markers of inflammation in pa- tients with acute myocardial infarction. Experimental and Therapeutic Medicine. 2017;14(5):4942–50. DOI:10.3892/etm.2017.5175

16. Guimarães ES, Cerda A, Dorea EL, Bernik MMS, Gusukuma MC, Pinto GA et al. Effects of short-term add-on ezetimibe to statin treat- ment on expression of adipokines and inflammatory markers in diabetic and dyslipidemic patients. Cardiovascular Therapeutics. 2017;35(6): e12307. DOI:10.1111/1755-5922.12307

17. Crea F, Niccoli G. Ezetimibe and Plaque Regression: Cholesterol Lowering or Pleiotropic Effects? Journal of the American College of Cardiology. 2015;66(5):508–10. DOI:10.1016/j.jacc.2015.05.064

18. Sternberg Z, Chichelli T, Sternberg D, Hojnacki D, Drake A, Liu S et al. Quantitative and qualitative pleiotropic differences between Simvastatin single and Vytorin combination therapy in hypercholesterolemic sub- jects. Atherosclerosis. 2013;231(2):411–20. DOI:10.1016/j.atherosclerosis.2013.09.031

19. Muñoz-Pacheco P, Ortega-Hernández A, Miana M, Cachofeiro V, Fernández-Cruz A, Gómez-Garre D. Ezetimibe inhibits PMA-induced monocyte/macrophage differentiation by altering microRNA expres- sion: A novel anti-atherosclerotic mechanism. Pharmacological Research. 2012;66(6):536–43. DOI:10.1016/j.phrs.2012.09.005

20. Qin L, Yang Y-B, Yang Y-X, Gong Y-Z, Li X-L, Li G-Y et al. Inhibition of Smooth Muscle Cell Proliferation by Ezetimibe via the Cyclin D1-MAPK Pathway. Journal of Pharmacological Sciences. 2014;125(3):283–91. DOI:10.1254/jphs.13239FP

21. Akdim F, van Leuven S, P. Kastelein J, G. Stroes E. Pleiotropic Effects of Statins: Stabilization of the Vulnerable Atherosclerotic Plaque? Current Pharmaceutical Design. 2007;13(10):1003–12. DOI:10.2174/138161207780487548

22. Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K et al. Impact of Dual Lipid-Lowering Strategy with Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients with Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial. Journal of the American College of Cardiology. 2015;66(5):495–507. DOI:10.1016/j.jacc.2015.05.065

23. Hougaard M, Hansen HS, Thayssen P, Antonsen L, Junker A, Veien K et al. Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovascular Revascularization Medicine. 2017;18(2):110–7. DOI:10.1016/j.carrev.2016.11.010

24. Mirzaee S, Thein PM, Nogic J, Nerlekar N, Nasis A, Brown AJ. The ef- fect of combined ezetimibe and statin therapy versus statin therapy alone on coronary plaque volume assessed by intravascular ultrasound: A systematic review and meta-analysis. Journal of Clinical Lipidology. 2018;12(5):1133-1140.e15. DOI:10.1016/j.jacl.2018.06.001

25. Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E et al. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemor- rhagic stroke and cataract. European Heart Journal. 2018;39(27):2526– 39. DOI:10.1093/eurheartj/ehy182

26. Toth PP, Catapano AL, Farnier M, Foody J, Tomassini JE, Jensen E et al. Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients with Nondiabetic Hypercholesterolemia. The American Journal of Cardiology. 2016;118(12):1812–20. DOI:10.1016/j.amjcard.2016.08.071

27. Barkas F, Elisaf M, Liberopoulos E, Klouras E, Liamis G, Rizos EC. Statin therapy with or without ezetimibe and the progression to diabe- tes. Journal of Clinical Lipidology. 2016;10(2):306–13. DOI: 10.1016/j.jacl.2015.11.015

28. Wu H, Shang H, Wu J. Effect of ezetimibe on glycemic control: a system- atic review and meta-analysis of randomized controlled trials. Endocrine. 2018;60(2):229–39. DOI:10.1007/s12020-018-1541-4

29. Ohbu-Murayama K, Adachi H, Hirai Y, Enomoto M, Fukami A, Obuchi A et al. Ezetimibe combined with standard diet and exer- cise therapy improves insulin resistance and atherosclerotic markers in patients with metabolic syndrome. Journal of Diabetes Investigation. 2015;6(3):325–33. DOI:10.1111/jdi.12298

30. Nakamura A, Sato K, Kanazawa M, Kondo M, Endo H, Takahashi T et al. Impact of decreased insulin resistance by ezetimibe on postpran- dial lipid profiles and endothelial functions in obese, non-diabetic-meta- bolic syndrome patients with coronary artery disease. Heart and Vessels. 2019;34(6):916–25. DOI:10.1007/s00380-018-1319-x

31. Yagi S, Akaike M, Aihara K, Iwase T, Ishikawa K, Yoshida S et al. Ezetimibe Ameliorates Metabolic Disorders and Microalbuminuria in Patients with Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis. 2010;17(2):173–80. DOI:10.5551/jat.2378

32. Sears B, Perry M. The role of fatty acids in insulin resistance. Lipids in Health and Disease. 2015;14(1):121. DOI:10.1186/s12944-015-0123-1

33. Kim D, Touros A, Kim WR. Nonalcoholic Fatty Liver Disease and Metabolic Syndrome. Clinics in Liver Disease. 2018;22(1):133–40. DOI:10.1016/j.cld.2017.08.010

34. Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Askling J et al. Cardiovascular risk factors in non-alcoholic fatty liver disease. Liver International. 2019;39(1):197–204. DOI:10.1111/liv.13973

35. Nakade Y, Murotani K, Inoue T, Kobayashi Y, Yamamoto T, Ishii N et al. Ezetimibe for the treatment of non-alcoholic fatty liver disease: A meta- analysis. Hepatology Research. 2017;47(13):1417–28. DOI:10.1111/hepr.12887

36. Lee HY, Jun DW, Kim HJ, Oh H, Saeed WK, Ahn H et al. Ezetimibe dec- reased nonalcoholic fatty liver disease activity score but not hepatic ste- atosis. The Korean Journal of Internal Medicine. 2019;34(2):296–304. DOI:10.3904/kjim.2017.194

37. Толкачева В. В., Малая И. П., Багманова Н. Х., Кобалава Ж. Д. Изуче- ние биоэквивалентности препаратов эзетимиба у здоровых доброволь- цев после однократного приема натощак. Consilium Medicum. 2019;21(1):87–91. DOI:10.26442/20751753.2019.1.190205

38. Кобалава Ж. Д., Гуревич В. С., Галявич А. С., Каминный А.И., Кашталап В.В., Мареев В.Ю. и др. Возможности клинического применения препарата эзетимиба Отрио (АО «Акри- хин», Россия) у пациентов высокого и очень высокого сердечно- сосудистого риска, не достигших целевых значений показателей липидного обмена. заключение совета экспертов. Кардиология. 2019;59(5S):47-57. DOI:10.18087/cardio.n581

39. Kalogirou M, Tsimihodimos V, Elisaf M. Pleiotropic effects of ezetimibe: Do they really exist? European Journal of Pharmacology. 2010;633 (1–3):62–70. DOI:10.1016/j.ejphar.2010.02.003


Для цитирования:


Шапошник И.И., Генкель В.В. Плейотропные эффекты эзетимиба. Кардиология. 2019;59(12S):12-17. https://doi.org/10.18087/cardio.n875

For citation:


Shaposhnik I.I., Genkel V.V. Pleiotropic effects of ezetimibe. Kardiologiia. 2019;59(12S):12-17. (In Russ.) https://doi.org/10.18087/cardio.n875

Просмотров: 328


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0022-9040 (Print)
ISSN 2412-5660 (Online)